Classification of current anticancer immunotherapies

Galluzzi, L., Vacchelli, E., Bravo-San Pedro, J. M., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J. P., Agostinis, P., Aranda, F., Apte, R. N., Ayyoub, M., Beckhove, P., Blay, J. Y., Bracci, L., Caignard, A., Castelli, C., Cavallo, F., Celis, E., Cerundolo, F., Clayton, Aled ORCID: https://orcid.org/0000-0002-3087-9226, Colombo, M. P., Coussens, L., Dhodapkar, M. V., Eggermont, A. M., Fearon, D. T., Fridman, W. H., Fučíková, J., Gabrilovich, D., Galon, J., Garg, A., Ghiringhelli, F., Giaccone, G., Gilboa, E., Gnjatic, S., Hoos, A., Hosmalin, A., Jäger, D., Kalinski, P., Kärre, K., Kepp, O., Kiessling, R., Kirkwood, J. M., Klein, E., Knuth, A., Lewis, C. E., Liblau, R., Lotze, M. T., Lugli, E., Mach, J. P., Mattei, F., Mavilio, D., Melero, I., Melief, C. J., Mittendorf, E. A., Moretta, L., Odunsi, A., Okada, H., Palucka, A. K., Peter, M. E., Pienta, K. J., Porgador, A., Prendergast, G. C., Rabinovich, G. A., Restifo, N. P., Rizvi, N., Sautès-Fridman, C., Schreiber, H., Seliger, B., Shiku, H., Silva-Santos, B., Smyth, M. J., Speiser, D. E., Spisek, R., Srivastava, P. K., Talmadge, J. E., Tartour, E., Van Der Burg, S. E., Van Den Eynde, B. J., Vile, R., Wagner, H, Webster, J. S., Whiteside, T. L., Wolchok, J. D., Zitvogel, L., Zou, W. and Kroemer, G. 2014. Classification of current anticancer immunotherapies. Oncotargets and Therapy 5 (24) , pp. 12472-12508. 10.18632/oncotarget.2998

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Subjects:	Q Science > QR Microbiology > QR180 Immunology R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords:	adoptive cell transfer, checkpoint blockers, dendritic cell-based interventions, DNA-based vaccines, immunostimulatory cytokines, peptide-based vaccines, oncolytic viruses, Toll-like receptor agonists
Publisher:	Dove Medical Press
ISSN:	1178-6930
Related URLs:	http://www.dovepress.com/oncotargets-and...
Date of First Compliant Deposit:	19 July 2017
Date of Acceptance:	15 December 2014
Last Modified:	12 May 2023 13:07
URI:	https://orca.cardiff.ac.uk/id/eprint/69724

Citation Data

Cited 370 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item